YKYang-Ki Kim

Yang-Ki Kim

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Yang-Ki Kim has a total of 93 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Clinical strategies for perioperative management of direct oral anticoagulants in patients treated for venous thromboembolism

    by Hun-Gyu Hwang, Jinwoo Seok, Yang-Ki Kim

    Purpose: Venous thromboembolism (VTE) is increasing in prevalence in Korea. Direct oral anticoagulants (DOACs)—including apixaban, rivaroxaban, edoxaban, and dabigatran—are now the standard treatment of VTE. A growing number of patients on these agents require procedures or surgery, yet optimal perioperative management remains unclear.Current Concepts: Appropriate perioperative management of DOACs is essential to minimize both bleeding and thromboembolic complications. Procedure-related hemorrhagerisk can be categorized as minimal (e.g., minor dental or cataract procedures), low to moderate (e.g., arthroscopy, cutaneous or lymph node biopsies, laparoscopic cholecystectomy, or inguinal hernia repair), or high risk (e.g., cancer or orthopedic surgery). Given the rapid onset and short half-life of DOACs, bridging therapy is rarely needed. For procedures with minimal bleeding risk, DOACs can generally be continued or withheld only on the day of the procedure. For low to moderate bleeding risk, the recommendation is to stop DOACs one day before and resume one day after the procedure. For high-risk procedures, DOACs should be discontinued two days prior and restarted two days post-procedure.Discussion and Conclusion: With Korea’s aging population and improved cancer survival rates, clinicians are increasingly encountering patients on DOACs in the perioperative setting. However, some practitioners continue to rely on outdated practices based on warfarin or antiplatelet therapy. Improved outcomes require individualized DOAC management, tailored according to the specific agent, procedure-related bleeding risk, thromboembolic risk, and renal function. Promoting adherence to current, evidence-based protocols will optimize safety and efficacy for patients undergoing procedures while receiving DOAC therapy.

  • Open Access

    Direct Oral Anticoagulants in Antiphospholipid Syndrome-Associated Venous Thromboembolism: Real World Evidence

    by Hun-Gyu Hwang, Ju Hyun Lee, Sang-A Kim, Yang-Ki Kim, Myung-Shin Kim, Junshik Hong, Ho-Young Yhim, Soo-Mee Bang

    Hwang HG, et al. J Korean Med Sci. 2024 Jul;39:e252. https://doi.org/10.3346/jkms.2024.39.e252


  • Open Access

    Pharmacotherapy for pulmonary embolism: new anticoagulants

    by Hun-Gyu Hwang, Yang-Ki Kim

    Background: Pulmonary embolism is associated with reduced survival and considerable economic burden worldwide. In Korea, the incidence of pulmonary embolism has been gradually increasing. Older individuals are at an increased risk for pulmonary embolism and anticoagulation-related bleeding events. Typically, heparin and vitamin K antagonists are employed to treat pulmonary embolism; however, these agents present numerous limitations. Hence, novel anticoagulants with improved safety and efficacy profiles are urgently needed.Current Concepts: Direct oral anticoagulants (DOACs), including direct thrombin (coagulation factor II) inhibitors and selective inhibitors of coagulation factor Xa, have emerged as alternative agents. Phase III, large-scale clinical trials have revealed that DOACs are non-inferior to standard therapy during initial and long-term treatment of pulmonary embolism, considering the safety profile. Evidence-based clinical guidelines recommend that primary care clinicians employ DOACs over warfarin to achieve anticoagulation.Discussion and Conclusion: For over 70 years, the standard therapy for most patients with pulmonary embolism has involved heparin administration, overlapped and followed by a vitamin K antagonist. Recently developed DOACs against coagulation factor Xa or thrombin might overcome limitations of standard therapy, including the need for injection and regular dose adjustment with laboratory monitoring. These limitations hinder the management of patients with pulmonary embolism and negatively impact the patient’s quality of life. Four DOACs, including apixaban, dabigatran, edoxaban, and rivaroxaban, are currently available for treating pulmonary embolism in Korea, which could simplify the therapeutic strategy.

  • Open Access

    Incidence of Venous Thromboembolism: The 3rdKorean Nationwide Study

    by Hun-Gyu Hwang, Ju Hyun Lee, Sang-A Kim, Yang-Ki Kim, Ho-Young Yhim, Junshik Hong, Soo-Mee Bang

    Hwang HG, et al. J Korean Med Sci. 2022 Apr;37(17):e130. https://doi.org/10.3346/jkms.2022.37.e130


  • Open Access

    Electronic Cigarette or Vaping Product Use-Associated Lung Injury: A Case Report

    by Jiyun Lim, Bo Da Nam, Jung Hwa Hwang, Yang-Ki Kim, Eunsun Oh, Eun Ji Lee

    임지윤, et al. J Korean Soc Radiol. 2021 Aug;82:e107. https://doi.org/10.3348/jksr.2020.0200


  • Open Access

    Venous thromboembolism associated with combined oral contraceptive use: a single-institution experience

    by Yong-Su Jang, Eun Sil Lee, Yang-Ki Kim

    Objective Combined oral contraceptives (COCs) are used for various reasons. However, venous thromboembolism (VTE), a significant side effect, can be fatal. This study reports the first case series in Korea involving patients with COC-associated VTE registered at a university hospital.Methods This study recruited 13 patients diagnosed with COC-associated VTE between June 2006 and May 2018. Risk factors, including age, body mass index, smoking habits, estrogen dosage, type of progestin, and duration of COC use, were evaluated.Results Among patients with VTE, 9 showed pulmonary embolism (PE) concomitant with deep vein thrombosis (DVT). However, the remaining patients showed DVT (1 patient), PE (1 patient), and cerebral venous thrombosis (2 patients). The median duration between the onset of symptoms and a hospital visit was 3 days, and it sometimes took as long as 32 days. Among the 10 patients with PE, 1 high-risk group and 2 intermediate-high risk groups were treated with tissue plasminogen activators before anticoagulants. There were no cases of recurrence among patients who continued to take anticoagulants for 3 months.Conclusion These findings emphasize that healthcare professionals who prescribe or dispense COCs to women must inform them of the risk of VTE, including the risk factors, differences in risk depending on the type of progestin present in the product, and pertinent signs and symptoms. Efforts should also be made to inform patients of VTE, even through information campaigns such as brochures. Most importantly, women should remain alert for signs and symptoms of VTE when using COCs.


  • The increased risk of bleeding due to drug-drug interactions in patients administered direct oral anticoagulants

    by Ji Yun Lee, Il-Young Oh, Ju-Hyeon Lee, Sang-Young Kim, Seong Soon Kwon, Hyeon-Jong Yang, Yang-Ki Kim, Soo-Mee Bang


  • Open Access

    Rifampin-Induced Immune Hemolytic Anemia during Treatment of Pulmonary Tuberculosis in a Patient with Primary Sjogren's Syndrome

    by Jin-Woo Souk, Yang-Ki Kim, Gae-Eil Jang, Hyun-Seok Jeong, Soo-Taek Uh, Ki-Up Kim, So-My Koo, Bo-Young Lee, Hyunjin Noh, Woo Yong Shin, et al.

    Jin-Woo Souk, Yang-Ki Kim, Gae-Eil Jang, Hyun-Seok Jeong, Soo-Taek Uh, Ki-Up Kim, So-My Koo, Bo-Young Lee, Hyunjin Noh, Woo Yong Shin, Jeong Won Shin, So-Young Jin. KJBT 2019;30:246-52. https://doi.org/10.17945/kjbt.2019.30.3.246

  • Open Access

    Quality Assessment of Oral Anticoagulation by Time in Therapeutic Range in Patients with Venous Thromboembolism in Korea

    by Hun-Gyu Hwang, Myung Shin Kim, Gune-Il Lim, So-My Koo, Bo Young Lee, Jun Yong Chang, Ki-Up Kim, Rojin Park, Juneyoung Lee, Soo-Taek Uh, et al.

    Purpose: To assess the efficacy and safety of oral anticoagulation with warfarin by time in therapeutic range in patients with venous thromboembolism (VTE) in South Korea. Methods: This was a retrospective, single-center study to evaluate patients diagnosed with VTE and managed with adjusted dose of warfarin over two-thirds of follow-up period in Thrombosis Clinic between February 2009 and August 2010. Validated dosing algorithm was used to manage the international normalized ratio (INR). Time in therapeutic range was calculated by Rosendaal method. Results: The period of predetermined warfarin interruption for peri-operative management (1 week preoperatively and 3 weeks post-operatively) was censored. It was not analyzed in 34 episodes. Out of 76 patients with VTE, 47 (23 men; mean age 64.9 years) were analyzed. Approximately two-thirds (31/47) of patients were warfarin-naïve. Total number of admissions was 84. Expected duration of anticoagulation was 6 months in 22 patients (47%), 12 months in 1 (2%), and indefinite in 24 (51%). There were various comorbidities, including active malignancy in 7 patients (15%), mycobacterium tuberculosis on rifampicin in 4 (8.5%), chronic kidney disease in 4 (8.5%), and hemorrhagic cerebral infarct in 1 (2%). Overall time in therapeutic range (TTR) was 52.4%. Most proportion of out-of-range was below the therapeutic range (29.5%). There was no thromboembolic complication, although two cases of major bleeding complications were observed. Conclusion: The validated dosing algorithm is effective for managing INRs in patients with VTE in Korea.

  • Open Access

    Screening and Treatment of Latent Tuberculosis Infection among Healthcare Workers at a Referral Hospital in Korea

    by Se Yoon Park, Eunyoung Lee, Eun Jung Lee, Tae Hyong Kim, Yang-Ki Kim

    Healthcare workers (HCWs) have a high risk of tuberculosis (TB) infection. Since August 2017, Korea has mandated the testing of latent TB infection (LTBI) and recommended treatment from HCWs at medical institutions. However, the acceptance/completion rate and adverse events of LTBI treatment have not been analyzed. From February to August 2017, we conducted a retrospective study at a referral university hospital in Korea, to screen the interferon-gamma release assay (IGRA) tests conducted for all HCWs for detecting and treating LTBI. HCWs diagnosed with LTBI were offered a 9-month isoniazid (9H), 3-month isoniazid/rifampin (3HR), or 4-month rifampin regimen. We investigated the acceptance/completion rate, adverse events, and causes of discontinuation or change in LTBI medication. A major adverse event was one wherein a patient had any adverse event ≥grade 3 causing LTBI treatment interruption. Of the 1,538 HCWs, 1,379 underwent IGRA testing for LTBI. Among them, 13.6% (187/1,379) tested positive and 73.3% (137/187) received treatment. The overall completion rate was 97.8% (134/137). HCWs were significantly more likely to complete first-line therapy with 3HR than with 9H (91.4% vs. 76.7%, P = 0.02). The most common major adverse event was hepatotoxicity (n = 7), followed by thrombocytopenia (n = 1) and anaphylactic shock (n = 1). Hepatotoxicity and hepatotoxicity (≥ grade 2) were more frequent in 9H than in 3HR (39.5% vs. 17.2%, P = 0.006 and 18.6% vs. 3.7%, P = 0.005, respectively). The median time to hepatotoxicity was 96 days (interquartile range, 20 - 103 days). Completion of first-line therapy for LTBI is more likely with 3HR than with 9H. This might be related to the development of hepatotoxicity after around 3 months of treatment. Anaphylactic shock and platelet count should be carefully monitored in those receiving rifampin-containing regimens.